Literature DB >> 19966208

Inhibition of Th2 adaptive immune responses and pulmonary inflammation by leukocyte Ig-like receptor B4 on dendritic cells.

Rebecca G Breslow1, Jayanti J Rao, Wei Xing, David I Hong, Nora A Barrett, Howard R Katz.   

Abstract

We previously established that the inhibitory receptor LILRB4 mitigates LPS-induced, neutrophil-dependent pathologic effector mechanisms in inflammation. We now report that LILRB4 on dendritic cells (DCs) counterregulates development of an adaptive Th2 immune response and ensuing inflammation in a model of allergic pulmonary inflammation, initiated by inhalation sensitization with OVA and LPS followed by airway challenge with OVA. We found that Lilrb4(-/-) mice had significantly exacerbated eosinophilic pulmonary inflammation, as assessed in bronchoalveolar lavage and lung tissue, as well as elevated levels of OVA-specific IgE and Th2 cytokines produced by OVA-restimulated lymph node cells. LILRB4 was preferentially expressed on MHC class II(high)CD86(high) OVA-bearing DCs in lung-draining lymph nodes after sensitization or challenge. Moreover, the lymph nodes of Lilrb4(-/-) mice had significantly more of these mature DCs after challenge with OVA, which was accompanied by significantly more IL-4-producing lymphocytes, compared with Lilrb4(+/+) mice. Sensitization of naive Lilrb4(+/+) mice by transfer of OVA-LPS-pulsed Lilrb4(-/-) bone marrow-derived DCs was sufficient to confer exacerbated allergic lung pathology upon challenge with OVA, compared with mice that received Lilrb4(+/+) bone marrow-derived DCs. Our findings establish that maturation and migration of pulmonary DCs to lymph nodes in response to Ag and an innate immune stimulus is associated with upregulated expression of LILRB4. In addition, this receptor attenuates the number of these mature DCs and attendant IL-4-producing lymphocytes in the lymph nodes, and accordingly, the ability of DCs to elicit pathologic Th2 pulmonary inflammation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19966208      PMCID: PMC2836496          DOI: 10.4049/jimmunol.0900877

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  gp49B1 deficiency is associated with increases in cytokine and chemokine production and severity of proliferative synovitis induced by anti-type II collagen mAb.

Authors:  Joseph S Zhou; Daniel S Friend; David M Lee; Lin Li; K Frank Austen; Howard R Katz
Journal:  Eur J Immunol       Date:  2005-05       Impact factor: 5.532

2.  Inhibitory receptor gp49B regulates eosinophil infiltration during allergic inflammation.

Authors:  Hillary H Norris; Mary E Peterson; Chris C Stebbins; Brittany W McConchie; Virgilio G Bundoc; Shweta Trivedi; Marcus G Hodges; Robert M Anthony; Joseph F Urban; Eric O Long; Andrea M Keane-Myers
Journal:  J Leukoc Biol       Date:  2007-08-30       Impact factor: 4.962

3.  Antigen and lipopolysaccharide play synergistic roles in the effector phase of airway inflammation in mice.

Authors:  Yong Woo Jung; Trenton R Schoeb; Casey T Weaver; David D Chaplin
Journal:  Am J Pathol       Date:  2006-05       Impact factor: 4.307

4.  New assay to detect low-affinity interactions and characterization of leukocyte receptors for collagen including leukocyte-associated Ig-like receptor-1 (LAIR-1).

Authors:  Lei Jiang; A Neil Barclay
Journal:  Eur J Immunol       Date:  2009-04       Impact factor: 5.532

5.  A novel regulatory role of gp49B on dendritic cells in T-cell priming.

Authors:  Satoshi Kasai; Masanori Inui; Kyohei Nakamura; Yuta Kakizaki; Shota Endo; Akira Nakamura; Sadayoshi Ito; Toshiyuki Takai
Journal:  Eur J Immunol       Date:  2008-09       Impact factor: 5.532

6.  Allergic airways disease develops after an increase in allergen capture and processing in the airway mucosa.

Authors:  Christophe von Garnier; Matthew E Wikstrom; Graeme Zosky; Debra J Turner; Peter D Sly; Miranda Smith; Jennifer A Thomas; Samantha R Judd; Deborah H Strickland; Patrick G Holt; Philip A Stumbles
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

7.  Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells.

Authors:  Deborah H Strickland; Philip A Stumbles; Graeme R Zosky; Lily S Subrata; Jenny A Thomas; Debra J Turner; Peter D Sly; Patrick G Holt
Journal:  J Exp Med       Date:  2006-11-06       Impact factor: 14.307

8.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells.

Authors:  Mirjam Kool; Thomas Soullié; Menno van Nimwegen; Monique A M Willart; Femke Muskens; Steffen Jung; Henk C Hoogsteden; Hamida Hammad; Bart N Lambrecht
Journal:  J Exp Med       Date:  2008-03-24       Impact factor: 14.307

9.  Mast cell deficiency in Kit(W-sh) mice does not impair antibody-mediated arthritis.

Authors:  Joseph S Zhou; Wei Xing; Daniel S Friend; K Frank Austen; Howard R Katz
Journal:  J Exp Med       Date:  2007-11-06       Impact factor: 14.307

10.  Immunoglobulin-like transcript 3-Fc suppresses T-cell responses to allogeneic human islet transplants in hu-NOD/SCID mice.

Authors:  George Vlad; Vivette D D'Agati; Qing-Yin Zhang; Zhuoru Liu; Eric K Ho; Thalachallour Mohanakumar; Mark A Hardy; Raffaello Cortesini; Nicole Suciu-Foca
Journal:  Diabetes       Date:  2008-04-16       Impact factor: 9.461

View more
  5 in total

1.  Downregulation of key early events in the mobilization of antigen-bearing dendritic cells by leukocyte immunoglobulin-like Receptor B4 in a mouse model of allergic pulmonary inflammation.

Authors:  Laura B Fanning; Carolyn C Buckley; Wei Xing; Rebecca G Breslow; Howard R Katz
Journal:  PLoS One       Date:  2013-02-19       Impact factor: 3.240

2.  Leukocyte immunoglobulin-like receptor B4 deficiency exacerbates acute lung injury via NF-κB signaling in bone marrow-derived macrophages.

Authors:  Tao Qiu; Jiangqiao Zhou; Tianyu Wang; Zhongbao Chen; Xiaoxiong Ma; Long Zhang; Jilin Zou
Journal:  Biosci Rep       Date:  2019-06-14       Impact factor: 3.840

Review 3.  Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.

Authors:  Mi Deng; Heyu Chen; Xiaoye Liu; Ryan Huang; Yubo He; Byounggyu Yoo; Jingjing Xie; Samuel John; Ningyan Zhang; Zhiqiang An; Cheng Cheng Zhang
Journal:  Antib Ther       Date:  2021-02-09

4.  Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation.

Authors:  Ayumi Mitsune; Mitsuhiro Yamada; Naoya Fujino; Tadahisa Numakura; Tomohiro Ichikawa; Ayumi Suzuki; Shuichiro Matsumoto; Yoshiya Mitsuhashi; Koji Itakura; Tomonori Makiguchi; Akira Koarai; Tsutomu Tamada; Shota Endo; Toshiyuki Takai; Yoshinori Okada; Satoshi Suzuki; Masakazu Ichinose; Hisatoshi Sugiura
Journal:  Respir Res       Date:  2021-08-23

Review 5.  Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors.

Authors:  Xunlei Kang; Jaehyup Kim; Mi Deng; Samuel John; Heyu Chen; Guojin Wu; Hiep Phan; Cheng Cheng Zhang
Journal:  Cell Cycle       Date:  2016       Impact factor: 4.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.